These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36263183)

  • 1. Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma and its usefulness in immunotherapy.
    Che Y; Luo Z; Cao Y; Wang J; Xue Q; Sun N; He J
    Int J Biol Sci; 2022; 18(15):5913-5927. PubMed ID: 36263183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
    Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
    Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
    Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
    Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in large cell neuroendocrine carcinoma of the lung.
    Eichhorn F; Harms A; Warth A; Muley T; Winter H; Eichhorn ME
    Lung Cancer; 2018 Apr; 118():76-82. PubMed ID: 29572007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
    Shirasawa M; Yoshida T; Takayanagi D; Shiraishi K; Yagishita S; Sekine K; Kanda S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Hamada A; Kohno T; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
    Clin Lung Cancer; 2021 Jul; 22(4):282-291.e6. PubMed ID: 33722498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
    Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
    J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
    Guleria P; Kumar S; Malik PS; Jain D
    Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma.
    Odate S; Nakamura K; Onishi H; Kojima M; Uchiyama A; Nakano K; Kato M; Tanaka M; Katano M
    Lung Cancer; 2013 Mar; 79(3):205-14. PubMed ID: 23312550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large cell neuroendocrine carcinoma of the lungs: case report and literature review.
    Han Y; Pang L; Huang J; Chen J
    Ann Palliat Med; 2020 Sep; 9(5):3705-3709. PubMed ID: 33065807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in neuroendocrine tumors of the lung.
    Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
    Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms.
    Ferencz B; Megyesfalvi Z; Csende K; Fillinger J; Poór V; Lantos A; Pipek O; Sólyom-Tisza A; Rényi-Vámos F; Schelch K; Lang C; Schwendenwein A; Boettiger K; László V; Hoetzenecker K; Döme B; Berta J
    Lung Cancer; 2023 Jul; 181():107263. PubMed ID: 37270937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with
    Qin Y; Yu M; Zhou L; Jiang L; Huang M
    Immunotherapy; 2020 Mar; 12(4):223-227. PubMed ID: 32156177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung.
    Komiya T; Ravindra N; Powell E
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):365-370. PubMed ID: 33639649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.
    Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T
    Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
    Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches.
    Khan J; Yasinzai AQK; Matosz S; Khan M; Heneidi S; Mesa H; Chauhan A; Del Rivero J; Karim NA; Ullah A
    Clin Exp Med; 2023 Nov; 23(7):3947-3955. PubMed ID: 37060529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
    Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.